IMPACT OF MONOCLONAL ANTIBODY THERAPY ON CONTROL OF MODERATE TO SEVERE INFLAMMATORY BOWEL DISEASE

Abstract

This study reviews the efficacy and safety of monoclonal antibody therapy in the management of moderate to severe inflammatory bowel disease (IBD). The integrative review covers clinical trials and observational studies published in the last ten years, focusing on agents such as infliximab, adalimumab, vedolizumab and ustekinumab. The results indicate that these treatments are effective in inducing and maintaining clinical remission, in addition to significantly improving the quality of life of patients. However, prolonged use is associated with risks, such as serious infections, which require continuous monitoring. Variability in response to treatment highlights the need for personalized approaches. It is concluded that monoclonal antibodies play a crucial role in the management of IBD, but challenges such as safety and accessibility need to be addressed to optimize clinical outcomes.